Healthpeak Properties vs Align Technology
Side-by-side comparison of AI visibility scores, market position, and capabilities
Denver healthcare REIT (NYSE: DOC) $21B combined; Healthpeak + Physicians Realty Trust merger Mar 2024, life science labs (SF/SD/Boston) + 300+ MOBs, competing with Alexandria Real Estate and Ventas.
About
Healthpeak Properties, Inc. is a Denver, Colorado-based healthcare real estate investment trust — publicly traded on the New York Stock Exchange (NYSE: DOC) as an S&P 500 Real Estate component — owning, operating, and developing healthcare-focused real estate including life science laboratory buildings (biopharmaceutical R&D facilities in South San Francisco, San Diego, Boston), medical office buildings (outpatient care facilities adjacent to major hospital campuses), and continuing care retirement communities through approximately 400 employees. In March 2024, Healthpeak Properties (then trading as HCP/PEAK) completed its $21 billion merger of equals with Physicians Realty Trust (DOC — medical office REIT with 300+ medical outpatient buildings in 30+ states) — adopting Physicians Realty Trust's ticker symbol "DOC" and creating a $21 billion combined healthcare REIT with 60+ million square feet of life science labs, 18+ million square feet of medical office, and the most diversified healthcare real estate portfolio among public healthcare REITs. CEO Scott Brinker leads the combined company's strategy of capitalizing on the structural demand drivers for healthcare real estate: life science lab demand driven by NIH funding, private biopharma venture investment, and drug approval tailwinds — and medical office demand driven by the shift of healthcare delivery from hospital inpatient settings to outpatient ambulatory care facilities that require real estate closer to patient populations. Healthpeak's life science portfolio in the three dominant biotech clusters (San Francisco Bay Area, San Diego's Torrey Pines/UTC corridor, Boston's Kendall Square/Route 128 corridor) positions it in the markets where biopharma and biotech tenants require Class A laboratory space for drug discovery and development.
San Jose clear aligner orthodontics inventor (NASDAQ: ALGN) at $3.23B 2024 revenue; 20 million Invisalign patient milestone Q1 2025 across 280,000+ doctors with iTero Lumina scanner competing with 3M Clarity for orthodontic clear aligner prescriptions.
About
Align Technology, Inc. is a San Jose, California-based global medical device company — publicly traded on NASDAQ (NASDAQ: ALGN) as an S&P 500 component — operating as the inventor of the Invisalign System and the world leader in clear aligner orthodontics, reaching 20 million Invisalign patients treated worldwide in Q1 2025 through a network of 280,000+ Invisalign-trained doctors across 100+ countries. In fiscal year 2024, Align reported $3.23 billion in total revenue with Q4 2024 revenue of $995.2 million (+4.0% year-over-year). Align's product portfolio comprises the Invisalign System of clear aligners, iTero intraoral digital scanners (including the iTero Lumina with 3X wider field of capture in a 50% smaller wand), and exocad CAD/CAM software for digital dental workflows. Manufacturing is based in Mexico with treatment planning performed in Costa Rica. CEO Joseph Hogan joined from GE Healthcare in 2015. Founded 1997 by Zia Chishti and Kelsey Wirth in San Jose.
AI Visibility Head-to-Head
Key Details
Capabilities & Ecosystem
Integrations
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.